Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + G-CLAM in AML/MDS
NCT02921061Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Dose Limiting Toxicities up to 49 days. Started Nov 2016; status: completed.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02921061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921061.